Beneficial Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity.
Rodrigo W Alves de SouzaVanessa VoltarelliDavid GalloSidharth ShankarMichael S TiftMark YoungEdward GompertsAndrew GompertsLeo Edmond OtterbeinPublished in: Journal of the American Heart Association (2024)
These findings strongly support using HBI-002 as a cardioprotective agent that maintains the therapeutic benefits of doxorubicin cancer treatment while mitigating cardiac damage.